Navigation Links
SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Date:12/17/2007

an oral, multi-targeted tyrosine kinase inhibitor that inhibits the mutant forms of c-KIT, PDGFR and FLT3, and suppresses c-MET and c-RET. MP470 also suppresses the Rad51 protein, a critical component of double- stranded DNA repair in cancer cells. Preclinical testing of MP470 has identified anti-tumor activity against a wide spectrum of cancers and is synergistic with a variety of chemotherapy agents as well as radiation therapy. MP470 is currently being evaluated in a single agent Phase 1 trial in patients with solid tumors.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors, and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding the ability of our products to enter clinical trials and the potential validation of our discovery process to produce new compounds. SuperGen's products may not enter clinical trials, and even if these products do enter clinical testing, there is no assurance that these tests will be successful. Additionally, the early successes in preclinical work may not be a validation of our discovery process and past success may not predict future success. Othe
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
2. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Fla. , Nov. 25, 2014  Breckenridge ... into a multi-product ANDA agreement with Pii (Pharmaceutics ... ) under which Breckenridge and Pii expect to ... terms of the agreement, Pii will develop, manufacture ... and distribute the products under its own label.  ...
(Date:11/26/2014)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the ... conferences.  , 31 st NASDAQ Investor Program ... 2014 at 6:45 a.m. EST / 11:45 a.m. GMT. Iain ... provide an overview of the company and a business and financial ... in New York, NY on Tuesday, December ...
(Date:11/26/2014)... Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in New York on ... . Dr. Helen Torley , President and Chief ... presentation will be webcast through the "Investors" section of Halozyme,s ... be made available for 90 days following the event. To ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... , ST. LOUIS, Dec. 22 KV Pharmaceutical Company ... Exchange (the "Exchange") for its securities to continue to trade on ... Annual Report on Form 10-K for the Company,s fiscal year ended ... the Company is unable to file the 2009 Annual Report on ...
... Dec. 22 On the morning of December 17, 2009, ... the center,s 10,000th patient, an 81-year-old male with a tumor deep ... impossible. Gamma Knife surgery is performed using Elekta,s Leksell Gamma Knife ... precisely on brain tumors and other targets in the head. ...
Cached Medicine Technology:KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010 2KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010 3KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010 4KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010 5KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010 6KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010 7University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System 2University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System 3University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System 4
(Date:11/26/2014)... The Deptford Center for Rehabilitation ... partnership designed to improve the quality of life ... (CHF) patients in the South Jersey area. Working ... team will help CHF patients manage their condition ... pairs the Cardiac Recovery program at the Deptford ...
(Date:11/26/2014)... November 26, 2014 German scientists say ... science can cause mesothelioma that looks and acts similar ... new article on the research. Click here to ... Institute for Toxicology and Experimental Medicine in Hannover injected ... all of the rats eventually developed mesothelioma , ...
(Date:11/26/2014)... 26, 2014 Loffler Companies has been ... in Imaging, an online information and news publication for ... the sixth consecutive year Loffler has earned this prestigious ... The Elite Dealer Awards honor the best and the ... Elite Dealer honorees were chosen for their innovative marketing ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with ... sales(at)researchmoz(dot)us , Researchmoz.us announces a new research report ... deep study of the report on the diabetes topic ... The global glucose monitoring market has a growth rate ... diabetics in the world. Their numbers have prompted the ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3
... Vitamins, Allows Class Participants to Download Free Weekly Classes at Oprah.com and ... ... March 31 Starting April 1,consumers who miss Oprah Winfrey and Eckhart ... can download,the event for free at Oprah.com or iTunes sponsored by new ...
... March 31 The American Stock Exchange(R),(Amex(R)) opened trading on ... Select Sector Index., Priced at $10.00 per unit with ... the ticker symbol HSJ and has a maturity,date of June ... The Amex specialist unit is,Wolverine Trading LLP., If you ...
... 31, 2008 /PRNewswire-FirstCall/ - Conseco, Inc.,(NYSE: CNO ) ... "As we stated when we issued preliminary results, ... Conseco for future profitable growth,",CEO Jim Prieur said. "New ... to be strong, and the expected future margins related ...
... PALO ALTO, Calif., March 31, 2008 ... 200-MS Series of ion trap,mass spectrometers for ... analytical chemists for the detection and characterization ... applications including,environmental, toxicology, food safety and agriculture. ...
... Parenthood, the Komen,Foundation is defeating its own mission of ... Life League denounced the claims made,in a recent Waco ... and "specious." The billboard ad draws a direct,connection between ... Waco,affiliate of Susan G. Komen for the Cure would ...
... 31 Varian, Inc.,(NasdaqGS: VARI) announced today the ... family of high performance gas chromatographs and application ... gas chromatograph models,and an associated range of analyzers ... applications. These new systems allow chemists,and engineers to ...
Cached Medicine News:Health News:Nature Made(R) Liquid Softgels Help Fuel Oprah's 'A New Earth' Web Event 2Health News:Conseco Reports Fourth Quarter and Year-End Results 2Health News:Conseco Reports Fourth Quarter and Year-End Results 3Health News:Conseco Reports Fourth Quarter and Year-End Results 4Health News:Conseco Reports Fourth Quarter and Year-End Results 5Health News:Conseco Reports Fourth Quarter and Year-End Results 6Health News:Conseco Reports Fourth Quarter and Year-End Results 7Health News:Conseco Reports Fourth Quarter and Year-End Results 8Health News:Conseco Reports Fourth Quarter and Year-End Results 9Health News:Conseco Reports Fourth Quarter and Year-End Results 10Health News:Conseco Reports Fourth Quarter and Year-End Results 11Health News:Conseco Reports Fourth Quarter and Year-End Results 12Health News:Conseco Reports Fourth Quarter and Year-End Results 13Health News:Conseco Reports Fourth Quarter and Year-End Results 14Health News:Conseco Reports Fourth Quarter and Year-End Results 15Health News:Conseco Reports Fourth Quarter and Year-End Results 16Health News:Conseco Reports Fourth Quarter and Year-End Results 17Health News:Conseco Reports Fourth Quarter and Year-End Results 18Health News:New Ion Trap Mass Spectrometers From Varian, Inc. Offer the Ultimate in Sensitive Detection and High Productivity 2Health News:Komen Foundation Support of Planned Parenthood 'Self-Defeating' 2Health News:New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications 2Health News:New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications 3
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
... The Netmon remote monitoring service ... be programmed and monitored from any ... The service enhances preventive maintenance ... may access the unit (with your ...
... a service that directly connects the ... customers laboratory to the Thermo Electron ... and Runcorn, U.K.* By using a ... site, high-value support services are made ...
The Shandon Citadel is a low cost, reliable, time-tested carousel-type tissue processor with convenient touch key operation. The Citadel 2000 has 110 cassette capacity and the Citadel 1000 has a cap...
Medicine Products: